ME Villarino, R Ridzon, PC Weismuller, M Elcock, RM Maxwell, J Meador, PJ Smith, ML Carson and LJ Geiter
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.

For persons infected with Mycobacterium tuberculosis resistant to isoniazid (INH), rifampin is recommended for the prevention of active disease. However, the adverse effects and acceptability of this preventive therapy are largely uncharacterized. We prospectively followed 157 high-school students exposed to, and probably infected with, M. tuberculosis strains resistant to INH. All 157 students were prescribed preventive therapy with rifampin (10 mg/kg up to 600 mg daily) for 24 wk. While receiving therapy, 41 (26%) reported one or more adverse effects; of these, 18 had therapy interrupted temporarily, two permanently. Four (2.5%) had alanine aminotransferase elevations greater than two times the upper limit of normal (range, 91 to 161 U/L); of these, one had therapy permanently stopped. Six (3.8%) self- discontinued therapy. No student was found to have active disease during the 2 yr of the study (exact 95% upper confidence limit, 2.2). We assumed that without preventive therapy, seven cases of tuberculosis would have occurred during these 2 yr. Therefore, we estimated that rifampin had a minimum protective effect of 56%. In conclusion, preventive therapy with rifampin was well tolerated and well accepted, and it appears effective in preventing active tuberculosis.

This article has been cited by other articles:

				T. W. Rennie, G. H. Bothamley, D. Engova, and I. P. Bates Patient choice promotes adherence in preventive treatment for latent tuberculosis Eur. Respir. J., October 1, 2007; 30(4): 728 - 735. [Abstract] [Full Text] [PDF]

				A. Lardizabal, M. Passannante, F. Kojakali, C. Hayden, and L. B. Reichman Enhancement of Treatment Completion for Latent Tuberculosis Infection With 4 Months of Rifampin Chest, December 1, 2006; 130(6): 1712 - 1717. [Abstract] [Full Text] [PDF]

				J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952. [Abstract] [Full Text] [PDF]

				K. R. Page, F. Sifakis, R. Montes de Oca, W. A. Cronin, M. C. Doherty, L. Federline, S. Bur, T. Walsh, W. Karney, J. Milman, et al. Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis: A Retrospective Study. Arch Intern Med, September 25, 2006; 166(17): 1863 - 1870. [Abstract] [Full Text] [PDF]

				H. M. Blumberg, M. K. Leonard Jr, and R. M. Jasmer Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection JAMA, June 8, 2005; 293(22): 2776 - 2784. [Abstract] [Full Text] [PDF]

				L. B. Reichman, A. Lardizabal, and C. H. Hayden Considering the Role of Four Months of Rifampin in the Treatment of Latent Tuberculosis Infection Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 832 - 835. [Full Text] [PDF]

				Pediatric Tuberculosis Collaborative Group Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infection in Children and Adolescents Pediatrics, October 1, 2004; 114(4/S2): 1175 - 1201. [Abstract] [Full Text] [PDF]

				D. Menzies, M.-J. Dion, B. Rabinovitch, S. Mannix, P. Brassard, and K. Schwartzman Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 445 - 449. [Abstract] [Full Text] [PDF]

				S. M. Marks, K. Ijaz, M. F. Iademarco, T. Sterling, S. S. Munsiff, T. R. Frieden, D. Menzies, K. Schwartzman, E. R. Jenny-Avital, K. Khan, et al. Management of Latent Tuberculosis Infection in Immigrants N. Engl. J. Med., March 27, 2003; 348(13): 1289 - 1292. [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				K. Schwartzman Latent tuberculosis infection: old problem, new priorities Can. Med. Assoc. J., March 1, 2002; 166(6): 759 - 761. [Full Text] [PDF]

				B. D. McNAB, D. D. MARCINIUK, R. A. ALVI, L. TAN, and V. H. HOEPPNER Twice Weekly Isoniazid and Rifampin Treatment of Latent Tuberculosis Infection in Canadian Plains Aborigines Am. J. Respir. Crit. Care Med., September 1, 2000; 162(3): 989 - 993. [Abstract] [Full Text]

				Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999. Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): S221 - 247. [Full Text] [PDF]

				A. Korzets and U. Gafter Tuberculosis prophylaxis for the chronically dialysed patient--yes or no? Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2857 - 2859. [Full Text] [PDF]

				R. S. Wallis, S. Patil, S.-H. Cheon, K. Edmonds, M. Phillips, M. D. Perkins, M. Joloba, A. Namale, J. L. Johnson, L. Teixeira, et al. Drug Tolerance in Mycobacterium tuberculosis Antimicrob. Agents Chemother., November 1, 1999; 43(11): 2600 - 2606. [Abstract] [Full Text]

				D. R. LEFF and A. R. LEFF Tuberculosis Control Policies in Major Metropolitan Health Departments in the United States . VI. Standard of Practice in 1996 Am. J. Respir. Crit. Care Med., November 1, 1997; 156(5): 1487 - 1494. [Abstract] [Full Text]